ketoconazole has been researched along with Aura in 2 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The efficacy evaluation of NPs/KCZ was evaluated in a kainic acid (KA)-induced mice model of epilepsy with carbamazepine (CBZ) treatment." | 8.12 | Functionalized PEG-PLA nanoparticles for brain targeted delivery of ketoconazole contribute to pregnane X receptor overexpressing in drug-resistant epilepsy. ( Fu, J; Lv, K; Sun, W; Wang, J; Yin, X; Zhang, J, 2022) |
| "The effect of ketoconazole (200 mg/d orally for 10 days) on the plasma concentrations of carbamazepine (CBZ) and its active metabolite carbamazepine-10,11-epoxide (CBZ-E) was assessed in eight patients with epilepsy stabilized on CBZ therapy." | 7.69 | Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. ( Arena, D; Fazio, A; Perucca, E; Pisani, F; Scordo, MG; Spina, E, 1997) |
| " The efficacy evaluation of NPs/KCZ was evaluated in a kainic acid (KA)-induced mice model of epilepsy with carbamazepine (CBZ) treatment." | 4.12 | Functionalized PEG-PLA nanoparticles for brain targeted delivery of ketoconazole contribute to pregnane X receptor overexpressing in drug-resistant epilepsy. ( Fu, J; Lv, K; Sun, W; Wang, J; Yin, X; Zhang, J, 2022) |
| "The effect of ketoconazole (200 mg/d orally for 10 days) on the plasma concentrations of carbamazepine (CBZ) and its active metabolite carbamazepine-10,11-epoxide (CBZ-E) was assessed in eight patients with epilepsy stabilized on CBZ therapy." | 3.69 | Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. ( Arena, D; Fazio, A; Perucca, E; Pisani, F; Scordo, MG; Spina, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Fu, J | 1 |
| Sun, W | 1 |
| Yin, X | 1 |
| Lv, K | 1 |
| Zhang, J | 1 |
| Spina, E | 1 |
| Arena, D | 1 |
| Scordo, MG | 1 |
| Fazio, A | 1 |
| Pisani, F | 1 |
| Perucca, E | 1 |
2 other studies available for ketoconazole and Aura
| Article | Year |
|---|---|
Functionalized PEG-PLA nanoparticles for brain targeted delivery of ketoconazole contribute to pregnane X receptor overexpressing in drug-resistant epilepsy.
Topics: Animals; Brain; Carbamazepine; Drug Resistant Epilepsy; Epilepsy; Kainic Acid; Ketoconazole; Mice; M | 2022 |
Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy.
Topics: Adult; Antifungal Agents; Carbamazepine; Drug Interactions; Drug Monitoring; Epilepsy; Female; Human | 1997 |